Literature DB >> 24097302

18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Johannes Salamon1, Simon Veldhoen, Ivayla Apostolova, Peter Bannas, Jin Yamamura, Jochen Herrmann, Reinhard E Friedrich, Gerhard Adam, Victor F Mautner, Thorsten Derlin.   

Abstract

OBJECTIVES: To evaluate the usefulness of normalising intra-tumour tracer accumulation on (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to reference tissue uptake for characterisation of peripheral nerve sheath tumours (PNSTs) in neurofibromatosis type 1 (NF1) compared with the established maximum standardised uptake value (SUVmax) cut-off of >3.5.
METHODS: Forty-nine patients underwent FDG PET/CT. Intra-tumour tracer uptake (SUVmax) was normalised to three different reference tissues (tumour-to-liver, tumour-to-muscle and tumour-to-fat ratios). Receiver operating characteristic (ROC) analyses were used out to assess the diagnostic performance. Histopathology and follow-up served as the reference standard.
RESULTS: Intra-tumour tracer uptake correlated significantly with liver uptake (rs= 0.58, P = 0.016). On ROC analysis, the optimum threshold for tumour-to-liver ratio was >2.6 (AUC = 0.9735). Both the SUVmax cut-off value of >3.5 and a tumour-to-liver ratio >2.6 provided a sensitivity of 100 %, but specificity was significantly higher for the latter (90.3% vs 79.8%; P = 0.013).
CONCLUSIONS: In patients with NF1, quantitative (18)F-FDG PET imaging may identify malignant change in neurofibromas with high accuracy. Specificity could be significantly increased by using the tumour-to-liver ratio. The authors recommend further evaluation of a tumour-to-liver ratio cut-off value of >2.6 for diagnostic intervention planning. KEY POINTS: • (18)F-FDG PET/CT is used for detecting malignancy in PNSTs in NF1 patients • An SUV max cut-off value may give false-positive results for benign plexiform neurofibromas • Specificity can be significantly increased using a tumour-to-liver ratio.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24097302     DOI: 10.1007/s00330-013-3020-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

Review 1.  Neurofibromatosis type 1 in childhood.

Authors:  R Listernick; J Charrow
Journal:  J Pediatr       Date:  1990-06       Impact factor: 4.406

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

3.  MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.

Authors:  V F Mautner; M Hartmann; L Kluwe; R E Friedrich; C Fünsterer
Journal:  Neuroradiology       Date:  2006-01-24       Impact factor: 2.804

Review 4.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

5.  MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas.

Authors:  Junji Wasa; Yoshihiro Nishida; Satoshi Tsukushi; Yoji Shido; Hideshi Sugiura; Hiroatsu Nakashima; Naoki Ishiguro
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

6.  Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis.

Authors:  R C Ramanathan; J M Thomas
Journal:  Eur J Surg Oncol       Date:  1999-04       Impact factor: 4.424

7.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.

Authors:  M A Khan; C S Combs; E M Brunt; V J Lowe; M K Wolverson; H Solomon; B T Collins; A M Di Bisceglie
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

8.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

9.  Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Authors:  Thorsten Derlin; Katharina Tornquist; Silvia Münster; Ivayla Apostolova; Christian Hagel; Reinhard E Friedrich; Ulrike Wedegärtner; Victor F Mautner
Journal:  Clin Nucl Med       Date:  2013-01       Impact factor: 7.794

10.  Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.

Authors:  Andreas K Buck; Ken Herrmann; Christian Meyer Zum Büschenfelde; Malik E Juweid; Mark Bischoff; Gerhard Glatting; Gregor Weirich; Peter Möller; Hans-Jürgen Wester; Klemens Scheidhauer; Tobias Dechow; Christian Peschel; Markus Schwaiger; Sven N Reske
Journal:  Clin Cancer Res       Date:  2008-04-29       Impact factor: 12.531

View more
  19 in total

1.  Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.

Authors:  J Uthoff; F A De Stefano; K Panzer; B W Darbro; T S Sato; R Khanna; D E Quelle; D K Meyerholz; J Weimer; J C Sieren
Journal:  J Neuroradiol       Date:  2018-06-27       Impact factor: 3.447

2.  18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.

Authors:  Francois Cornelis; Vlasios Sotirchos; Elena Violari; Constantinos T Sofocleous; Heiko Schoder; Jeremy C Durack; Robert H Siegelbaum; Majid Maybody; John Humm; Stephen B Solomon
Journal:  J Nucl Med       Date:  2016-02-23       Impact factor: 10.057

3.  Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.

Authors:  Christian Philipp Reinert; Martin Ulrich Schuhmann; Benjamin Bender; Isabel Gugel; Christian la Fougère; Jürgen Schäfer; Sergios Gatidis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-08       Impact factor: 9.236

4.  Malignant peripheral nerve sheath tumor of the vagus nerve: an uncommon cause of progressive dyspnea.

Authors:  Felipe Welter Langer; Daiane Dos Santos; Giordano Rafael Tronco Alves; Gustavo Suertegaray; Carlos Jesus Pereira Haygert
Journal:  Radiol Bras       Date:  2017 Nov-Dec

5.  Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.

Authors:  Lennart Well; Johannes Salamon; Michael G Kaul; Said Farschtschi; Jochen Herrmann; Karin I Geier; Christian Hagel; Maximilian Bockhorn; Peter Bannas; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

Review 6.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

7.  Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.

Authors:  Stephen M Broski; Geoffrey B Johnson; Benjamin M Howe; Mark A Nathan; Doris E Wenger; Robert J Spinner; Kimberly K Amrami
Journal:  Skeletal Radiol       Date:  2016-04-26       Impact factor: 2.199

8.  Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1.

Authors:  Charlie N Nelson; Eva Dombi; Jared S Rosenblum; Markku M Miettinen; Tanya J Lehky; Patricia O Whitcomb; Christina Hayes; Gretchen Scott; Sarah Benzo; Brigitte C Widemann; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2019-10-25       Impact factor: 5.115

9.  Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.

Authors:  Axel Van Der Gucht; Ouidad Zehou; Soraya Djelbani-Ahmed; Laurence Valeyrie-Allanore; Nicolas Ortonne; Pierre Brugières; Pierre Wolkenstein; Alain Luciani; Alain Rahmouni; Emilie Sbidian; Emmanuel Itti
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

10.  Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.

Authors:  Johannes Salamon; László Papp; Zoltán Tóth; Azien Laqmani; Ivayla Apostolova; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.